Active, Not Recruiting
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933
- Conditions
- ALK Positive Malignancies, Neoplasms
- Locations
-
- Highlands Oncology Group Fayetteville, Arkansas, United States
- Loma Linda University Loma Linda, California, United States
- University of Colorado Cancer Center Aurora, Colorado, United States
- Maryland Oncology Hematology P A Rockville, Maryland, United States